11314862|t|Mitochondrial medicine--molecular pathology of defective oxidative phosphorylation.
11314862|a|Different tissues display distinct sensitivities to defective mitochondrial oxidative phosphorylation (OXPHOS). Tissues highly dependent on oxygen such as the cardiac muscle, skeletal and smooth muscle, the central and peripheral nervous system, the kidney, and the insulin-producing pancreatic beta-cell are especially susceptible to defective OXPHOS. There is evidence that defective OXPHOS plays an important role in atherogenesis, in the pathogenesis of Alzheimer's disease, Parkinson's disease, diabetes, and aging. Defective OXPHOS may be caused by abnormal mitochondrial biosynthesis due to inherited or acquired mutations in the nuclear (n) or mitochondrial (mt) deoxyribonucleic acid (DNA). For instance, the presence of a mutation of the mtDNA in the pancreatic beta-cell impairs adenosine triphosphate (ATP) generation and insulin synthesis. The nuclear genome controls mitochondrial biosynthesis, but mtDNA has a much higher mutation rate than nDNA because it lacks histones and is exposed to the radical oxygen species (ROS) generated by the electron transport chain, and the mtDNA repair system is limited. Defective OXPHOS may be caused by insufficient fuel supply, by defective electron transport chain enzymes (Complexes I - IV), lack of the electron carrier coenzyme Q10, lack of oxygen due to ischemia or anemia, or excessive membrane leakage, resulting in insufficient mitochondrial inner membrane potential for ATP synthesis by the F0F1-ATPase. Human tissues can counteract OXPHOS defects by stimulating mitochondrial biosynthesis; however, above a certain threshold the lack of ATP causes cell death. Many agents affect OXPHOS. Several nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit or uncouple OXPHOS and induce the 'topical' phase of gastrointestinal ulcer formation. Uncoupled mitochondria reduce cell viability. The Helicobacter pylori induces uncoupling. The uncoupling that opens the membrane pores can activate apoptosis. Cholic acid in experimental atherogenic diets inhibits Complex IV, cocaine inhibits Complex I, the poliovirus inhibits Complex II, ceramide inhibits Complex III, azide, cyanide, chloroform, and methamphetamine inhibit Complex IV. Ethanol abuse and antiviral nucleoside analogue therapy inhibit mtDNA replication. By contrast, melatonin stimulates Complexes I and IV and Gingko biloba stimulates Complexes I and III. Oral Q10 supplementation is effective in treating cardiomyopathies and in restoring plasma levels reduced by the statin type of cholesterol-lowering drugs.
11314862	146	185	mitochondrial oxidative phosphorylation	Disease	MESH:D028361
11314862	187	193	OXPHOS	Disease	MESH:D028361
11314862	224	230	oxygen	Chemical	MESH:D010100
11314862	268	271	and	Disease	
11314862	299	302	and	Disease	
11314862	342	345	and	Disease	
11314862	350	357	insulin	Gene	3630
11314862	429	435	OXPHOS	Disease	MESH:D028361
11314862	470	476	OXPHOS	Disease	MESH:D028361
11314862	504	517	atherogenesis	Disease	MESH:D050197
11314862	542	561	Alzheimer's disease	Disease	MESH:D000544
11314862	563	582	Parkinson's disease	Disease	MESH:D010300
11314862	584	592	diabetes	Disease	MESH:D003920
11314862	594	597	and	Disease	
11314862	615	621	OXPHOS	Disease	MESH:D028361
11314862	874	896	adenosine triphosphate	Chemical	MESH:D000255
11314862	898	901	ATP	Chemical	MESH:D000255
11314862	914	917	and	Disease	
11314862	918	925	insulin	Gene	3630
11314862	1071	1074	and	Disease	
11314862	1093	1115	radical oxygen species	Chemical	-
11314862	1117	1120	ROS	Chemical	-
11314862	1165	1168	and	Disease	
11314862	1215	1221	OXPHOS	Disease	MESH:D028361
11314862	1360	1372	coenzyme Q10	Chemical	MESH:C024989
11314862	1382	1388	oxygen	Chemical	MESH:D010100
11314862	1396	1404	ischemia	Disease	MESH:D007511
11314862	1408	1414	anemia	Disease	MESH:D000740
11314862	1516	1519	ATP	Chemical	MESH:D000255
11314862	1537	1548	F0F1-ATPase	Gene	514
11314862	1550	1555	Human	Species	9606
11314862	1579	1585	OXPHOS	Disease	MESH:D028361
11314862	1684	1687	ATP	Chemical	MESH:D000255
11314862	1726	1732	OXPHOS	Disease	MESH:D028361
11314862	1808	1814	OXPHOS	Disease	MESH:D028361
11314862	1815	1818	and	Disease	
11314862	1849	1871	gastrointestinal ulcer	Disease	MESH:D014456
11314862	1933	1952	Helicobacter pylori	Species	210
11314862	2042	2053	Cholic acid	Chemical	MESH:D019826
11314862	2070	2081	atherogenic	Disease	MESH:D050197
11314862	2109	2116	cocaine	Chemical	MESH:D003042
11314862	2141	2151	poliovirus	Species	138950
11314862	2173	2181	ceramide	Chemical	MESH:D002518
11314862	2199	2202	III	Gene	
11314862	2204	2209	azide	Chemical	MESH:D001386
11314862	2211	2218	cyanide	Chemical	MESH:D003486
11314862	2220	2230	chloroform	Chemical	MESH:D002725
11314862	2232	2235	and	Disease	
11314862	2236	2251	methamphetamine	Chemical	MESH:D008694
11314862	2272	2285	Ethanol abuse	Disease	MESH:D000437
11314862	2286	2289	and	Disease	
11314862	2300	2310	nucleoside	Chemical	MESH:D009705
11314862	2368	2377	melatonin	Chemical	MESH:D008550
11314862	2401	2407	and IV	Disease	MESH:D006011
11314862	2408	2411	and	Disease	
11314862	2449	2452	and	Disease	
11314862	2463	2466	Q10	Chemical	MESH:C024989
11314862	2508	2524	cardiomyopathies	Disease	MESH:D009202
11314862	2525	2528	and	Disease	
11314862	2586	2597	cholesterol	Chemical	MESH:D002784
11314862	Association	MESH:D000255	514
11314862	Negative_Correlation	MESH:C024989	MESH:D002784
11314862	Association	MESH:D019826	MESH:D028361
11314862	Negative_Correlation	MESH:C024989	MESH:D009202
11314862	Association	MESH:C024989	MESH:D028361
11314862	Positive_Correlation	MESH:D008550	MESH:D006011
11314862	Association	MESH:D019826	MESH:D050197

